Haemanthus’s Red ‘a/e’ Logo Draws Four Designers’ Critique
Evans has raised $18.5 million for Haemanthus, whose first planned device scans pets’ blood, saliva and urine; four designers question the startup’s lone red-and-black wordmark.
By Amara Osei
5 min read
What's News
- In May 2025, Billy Evans had raised about $18.5 million for Haemanthus.
- Haemanthus expected its stamp-size human wearable to require about three years and $70 million to develop.
- Google Patents showed at least six Raman spectroscopy patent requests, with one granted.
- Haemanthus said “not Theranos 2.0”; Evans called it “Theranos 2.0” in the film that debuted in October.
- Elizabeth Holmes is serving an 11-year prison sentence for defrauding investors.
By Amara Osei
The New York Times reported in May 2025 that Billy Evans had raised about $18.5 million for Haemanthus; Fast Company found one revealed brand element, a black serif wordmark with a red “a/e” ligature.
Fast Company described the fused letters as an “ash” that also appears to serve as a standalone brand mark. Haemanthus uses the design on LinkedIn and X. Its LinkedIn account has no posts, while X was briefly active in 2025.
Fast Company counted 14 X posts, one containing only a Mark Zuckerberg quote: “In a world that's changing so fast, the biggest risk you can take is not taking any risk.” Fast Company asked Haemanthus on X and LinkedIn about the design and its intent. The startup had not responded by publication.
What is Haemanthus?
Fast Company reported that Evans is Elizabeth Holmes’s partner and that his plans sounded distinctly similar to Holmes’s approach at Theranos. Holmes is serving an 11-year prison sentence for defrauding investors.
At the time, Haemanthus stated explicitly on its official X account that it was “not Theranos 2.0.” On social media, the startup says, “Elizabeth Holmes has zero involvement in Haemanthus.”
That tension runs through You Can See Everything, the Nathan Fielder and Lance Oppenheim film that debuted in October. Evans calls Haemanthus “Theranos 2.0” in the film, which paints a different picture from the company’s denials.
Fast Company reported that film fans have searched for company details. They found a few on-record statements, some patent applications, two defunct social media accounts and one wordmark.
What has Haemanthus disclosed?
Evans said in a May 2025 New York Times interview that Haemanthus was “still in stealth mode.” Marketing materials reviewed by the Times say the initial device will use a laser to scan blood, saliva or urine from pets and analyze samples at the molecular level.
The Times described Haemanthus’s long-term goal as a stamp-size wearable for humans. The company expected about three years and $70 million to develop it.
The U.S. Patent and Trademark Office was examining Haemanthus’s trademark request as of publication. Google Patents showed at least six submitted patent requests for Raman spectroscopy systems, the diagnostic tool at the center of the proposed technology; one has been granted.
What does the logo signal?
Fast Company said no public information establishes Haemanthus’s brand intent. The four designers read its limited visual choices differently.
Jesse Reed, principal at Order Design, said:
“If you were showing me this wordmark and you wanted me to describe it without knowing what space it was in, I would probably categorize it as editorial. It's a high-contrast serif, which you see most commonly used in newspapers.
It could simply be for contrast against other sans-serif grotesques that are used in the biohealth industry. There is some connection there with the use of that ligature, which is a Latin character that was used mostly in Old English.
That, paired with that type choice—there's something that they're hinting at with this, potentially rooted in some deep human history. But are they doing that, or is it purely an aesthetic and they have no idea actually why they're choosing it? It might have no meaning whatsoever. And I don't even want to give Billy Evans any credit for anything.”
Thomas Kurppa, cofounder at Kurppa Hosk, said:
“The red is an obvious reference to blood, but the letterforms introduce something more ambiguous. There's a tension between scientific heritage and almost biological, ornamental expression.
Most biotech companies use design to communicate precision, clarity, and technological progress. Haemanthus takes almost the opposite approach: It's expressive, historical, and unusually ornamental.
In a field where scientific credibility is everything, that choice stands out, and it's almost mysterious. But distinction and earning trust are two very different things.”
Dariush Aghai, cofounder at Study Hall, said:
“A biotech company, particularly one with this history, needs to communicate scientific credibility, transparency, and trust. Instead, this feels more akin to the visual language of heritage luxury and private wealth.
We know the leadership comes from extraordinary means, and the identity projects their perception of prestige and credibility, rather than what their audience needs to trust them. Founders often mistake personal taste for brand strategy.
They build brands that reflect how they see themselves, rather than how they need to be understood.”
Teemu Suviala, global chief creative officer at Landor, said:
“When a company has such a limited public presence like Haemanthus does, its logo can end up carrying more meaning than it was designed to bear, which puts a lot of pressure on a single brand asset. We all read these things differently, based on our experience and interests.
And what's important to remember is that a logo is not a brand. We're missing all the other elements of a working design and communications system.
A brand is also an accumulated perception in people's minds: all the memories, associations, expectations and emotional connections built through every encounter with a company or a product. These are shaped by a complete brand identity system, products, experiences, communications, marketing, and rituals.
What I'm saying is, we are definitely not seeing everything here.”
Reed characterized the wordmark as editorial; Kurppa saw tension between scientific heritage and ornament; Aghai saw prestige over audience trust; Suviala said a logo cannot replace a complete identity system. Haemanthus has disclosed none of that broader system publicly. Until it does, the red-and-black mark must carry the burden Suviala says exceeds a logo’s design.
Original: x.com
More from Amara Osei
Show full bio
Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.
2,129 articles